Richard Keith Hacker, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 412 Como Rd, Lake Como, PA 18437 Phone: 570-798-2828 Fax: 570-798-2636 |
News Archive
City of Hope researchers received approval from the U.S. Food and Drug Administration (FDA) to conduct the first-in-human study of a neural stem cell-based therapy targeting recurrent high-grade gliomas, the most aggressive type of brain tumor. Karen S. Aboody, M.D., associate professor in City of Hope's Department of Neurosciences, leads the research team that developed this treatment strategy. Jana Portnow, M.D., assistant professor and assistant director of the Brain Tumor Program at City of Hope, is the principal investigator for the clinical trial.
Egalet Corporation ("Egalet") today reported business highlights and financial results for the year ended December 31, 2013. This marks the first time that Egalet is reporting its operating results as a public company.
The trial of Dr. Jayant Patel continues. In recent evidence at the court one of the operating theatre nurses revealed under oath to the Brisbane Supreme Court how staff had tried to deter former Bundaberg-based surgeon Jayant Patel from transferring an unstable patient from the theatre to ICU, where he died. There was earlier evidence that the man was bleeding uncontrollably and also allegations that Patel urged junior doctors not to tell anyone what happened.
Clearstone Central Laboratories, a leading global provider of clinical laboratory and centralized cardiac services for clinical trials, today announced the expansion of testing capabilities at its Toronto laboratory. Additional safety as well as esoteric testing capacity and capabilities will be added to the existing operations.
› Verified 2 days ago